株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ブデソニド吸入器市場: 市場機会分析および将来予測

Budesonide Inhaler Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

発行 Coherent Market Insights 商品コード 817594
出版日 ページ情報 英文 149 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.00円で換算しております。
Back to Top
ブデソニド吸入器市場: 市場機会分析および将来予測 Budesonide Inhaler Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
出版日: 2019年03月15日 ページ情報: 英文 149 Pages
概要

当レポートでは、ブデソニド吸入器の世界市場を調査し、市場の概要、タイプ、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の概要

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:製品タイプ別
    • 市場スニペット:投与タイプ別
    • 市場スニペット:含有量別
    • 市場スニペット:流通チャネル別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場のダイナミクス、規制、動向分析

  • マーケットダイナミクス
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な開発
  • 規制の状況
  • 製品回収
  • 疫学分析
  • 技術の概要
  • PEST分析
  • ファイブフォース分析

第4章 ブデソニド吸入器市場:製品タイプ別

  • イントロダクション
  • 吸入物
  • ネブライザー

第5章 ブデソニド吸入器市場:投与タイプ別

  • イントロダクション
  • エアロゾル
  • 乾燥粉末
  • サスペンション
  • スプレー

第6章 ブデソニド吸入器市場:含有量別

  • イントロダクション
  • mg

第7章 ブデソニド吸入器市場:流通経路別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 ブデソニド吸入器市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • 中南米
  • アフリカ
  • 中東

第9章 競争環境

  • 企業プロファイル
    • Pfizer, Inc.
    • Cipla Limited
    • Lupin Limited
    • Cosmo Pharmaceuticals
    • Takeda Pharmaceutical Company Ltd.
    • Manus Aktteva Biopharma LLP
    • Abbott Laboratories
    • Lunan Better Pharmaceutical
    • Novartis International AG (Sandoz)
    • Mylan N.V.
    • Skyepharma
    • AstraZeneca Plc.
    • Chiesi Farmaceutici S.p.A.
    • Orion Corporation
    • Santarus Inc.
    • Synmosa Biopharma Corporation
    • Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
  • アナリストの意見

第10章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Budesonide is an artificial glucocorticoid steroid related to the naturally-occurring hormone, cortisol or hydrocortisone, which is produced in the adrenal glands. It is used for treating asthma. Budesonide is sold under the brand name Pulmicort. Each budesonide inhaler is designed to provide 60 to 120 inhalations depending on the device. Increasing air population is expected to lead to high prevalence of asthma worldwide. According to World Health Organization (WHO), asthma is not just a public health problem for high income countries, as it occurs in all countries regardless of level of development. Over 80% of asthma deaths occur in low and lower-middle income countries. Asthma is under-diagnosed and under-treated, creating a substantial burden to individuals and families and possibly restricting individuals' activities for a lifetime.

Market Dynamics

The global demand for budesonide inhaler is expected to witness substantial growth over the forecast period, owing to increasing incidences and prevalence of asthma. According to the Global Asthma Report 2018, asthma causes around 1000 deaths every day and affects as many as 339 million people worldwide.

Furthermore, major players in the market are focused on developing new drug combinations for paediatric use. For instance, in January 2017, AstraZeneca announced that the U.S. FDA approved Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of asthma in paediatric patients aged 6 to 12 years. Budesonide/formoterol is already approved in the U.S. to treat asthma in patients 12 years and older and for the maintenance treatment of airflow obstruction in Chronic Obstructive Pulmonary Disease (COPD) in adults.

However, product recalls due to failure to meet regulatory guidelines is expected to hinder the market growth. For instance, in 2014, AstraZeneca's PULMICORT RESPULES (budesonide inhalation suspension) was recalled by the U.S. FDA as budesonide may be above or below the specification range, which can be harmful for the patients.

Key features of the study:

  • This report provides in-depth analysis of the budesonide inhaler market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global budesonide inhaler market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global budesonide inhaler market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for budesonide inhaler market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Budesonide Inhaler Market, By Product Type:
    • Inhalants
    • Nebulizer
  • Global Budesonide Inhaler Market, By Dosage:
    • Aerosols
    • Dry Powder
    • Suspension
    • Spray
  • Global Budesonide Inhaler Market, By Strength:
    • 0.25 mg
    • 0.5 mg
    • 1.0 mg
  • Global Budesonide Inhaler Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Budesonide Inhaler Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Product Type:
    • Inhalants
    • Nebulizer
      • By Dosage:
    • Aerosol
    • Dry Powder
    • Suspension
    • Spray
      • By Strength:
    • 0.25 mg
    • 0.5 mg
    • 1.0 mg
      • By Distributional Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Product Type:
    • Inhalants
    • Nebulizer
      • By Dosage:
    • Aerosol
    • Dry Powder
    • Suspension
    • Spray
      • By Strength:
    • 0.25 mg
    • 0.5 mg
    • 1.0 mg
      • By Distributional Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Product Type:
    • Inhalants
    • Nebulizer
      • By Dosage:
    • Aerosol
    • Dry Powder
    • Suspension
    • Spray
      • By Strength:
    • 0.25 mg
    • 0.5 mg
    • 1.0 mg
      • By Distributional Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Product Type:
    • Inhalants
    • Nebulizer
      • By Dosage:
    • Aerosol
    • Dry Powder
    • Suspension
    • Spray
      • By Strength:
    • 0.25 mg
    • 0.5 mg
    • 1.0 mg
      • By Distributional Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Product Type:
    • Inhalants
    • Nebulizer
      • By Dosage:
    • Aerosol
    • Dry Powder
    • Suspension
    • Spray
      • By Strength:
    • 0.25 mg
    • 0.5 mg
    • 1.0 mg
      • By Distributional Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Product Type:
    • Inhalants
    • Nebulizer
      • By Dosage:
    • Aerosol
    • Dry Powder
    • Suspension
    • Spray
      • By Strength:
    • 0.25 mg
    • 0.5 mg
    • 1.0 mg
      • By Distributional Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Company Profiles
    • Pfizer Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Cipla Limited
    • Lupin Limited
    • Cosmo Pharmaceuticals
    • Takeda Pharmaceutical Company Ltd.
    • Manus Aktteva Biopharma LLP
    • Abbott Laboratories
    • Lunan Better Pharmaceutical
    • Novartis International AG (Sandoz)
    • Mylan N.V.
    • Skyepharma,
    • AstraZeneca Plc.
    • Chiesi Farmaceutici S.p.A.
    • Orion Corporation
    • Santarus Inc.
    • Synmosa Biopharma Corporation
    • Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Dosage
    • Market Snippet, By Strength
    • Market Snippet, By Distributional Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Landscape
  • Product Recall
  • Epidemiology Analysis
  • Technology Overview
  • PEST Analysis
  • Porter's Five Forces Model

4. Global Budesonide Inhaler Market, By Product Type, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Inhalants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Nebulizers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

5. Global Budesonide Inhaler Market, By Dosage, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Aerosols
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Dry Powder
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Suspension
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Spray
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

6. Global Budesonide Inhaler Market, By Strength, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • 0.25mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • 0.5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • 1.0 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

7. Global Budesonide Inhaler Market, By Distributional Channel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

8. Global Budesonide Inhaler Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Strength, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distributional Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Strength, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distributional Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Strength, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distributional Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Strength, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distributional Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Strength, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distributional Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Dosage, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Strength, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distributional Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

9. Competitive Landscape

  • Company Profiles
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Cipla Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Lupin Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Cosmo Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Takeda Pharmaceutical Company Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Manus Aktteva Biopharma LLP
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Abbott Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Lunan Better Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis International AG (Sandoz)
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Skyepharma
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AstraZeneca Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Chiesi Farmaceutici S.p.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Orion Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Santarus Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Synmosa Biopharma Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top